View ValuationSilva Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Silva Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026お知らせ • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladeshお知らせ • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025お知らせ • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).お知らせ • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.お知らせ • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, BangladeshNew Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).お知らせ • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).お知らせ • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023お知らせ • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.お知らせ • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.お知らせ • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.お知らせ • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Silva Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:SILVAPHL - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026330-154-14-10N/A12/31/2025357-14538N/A9/30/2025371-1362024N/A6/30/2025384-133614N/A3/31/2025432-132-256N/A12/31/2024498-107-34-4N/A9/30/2024547-90-321N/A6/30/2024600-64-303N/A3/31/2024612-3112-17N/A12/31/2023638-28-1319N/A9/30/20236710-4444N/A6/30/202371733-1770N/A3/31/2023745570127N/A12/31/202274978-1123N/A9/30/20227608924137N/A6/30/2022779102-17161N/A3/31/2022805119-1183N/A12/31/202179311540179N/A9/30/202178811273166N/A6/30/202179912082159N/A3/31/202178011612138N/A12/31/2020776118-43130N/A9/30/2020788126-20172N/A6/30/2020763119-21151N/A3/31/202076912614209N/A12/31/2019767133N/A236N/A9/30/2019756131N/A205N/A6/30/2019732143N/A190N/A3/31/2019725136N/A162N/A12/31/2018707125N/A131N/A9/30/2018695123N/A120N/A6/30/201868593N/A134N/A3/31/2018687100N/A139N/A6/30/201760280N/A80N/A6/30/201658670N/A91N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SILVAPHLの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SILVAPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SILVAPHLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SILVAPHLの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SILVAPHLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SILVAPHLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:40終値2026/05/21 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silva Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026
お知らせ • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
お知らせ • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
お知らせ • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).
お知らせ • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).
Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.
お知らせ • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).
お知らせ • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024
Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
お知らせ • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023
お知らせ • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.
お知らせ • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.
お知らせ • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023
Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.
Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.
Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.
お知らせ • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020